

# Cell Therapy Market

TechSci Research Analysts in  
Conversation with:

**Dr. Salmaan Dalvi**

Chief Executive Officer at Global  
Regenerative Medicine Society



## Dr. Salmaan Dalvi

Chief Executive Officer at Global Regenerative Medicine Society

### Can you briefly introduce yourself and your expertise in the field of cell therapy?

Dr. Salmaan Dalvi- I am a recognized leader in the field of regenerative medicine and cell therapy, with over 15 years of experience in the field of cellular medicine and 35 years' experience in the Healthcare Sector. Currently, I serve as CEO of the Regenerative and Cellular Medicine Registry (RCMR-[www.rcmregistry.com](http://www.rcmregistry.com)) where I focus on expanding access to affordable stem cell therapies and driving patient-centred innovations in the field.

In my career have been instrumental in pioneering inclusive strategies for stem cell and blood donation, emphasizing diversity and community engagement to improve representation in cellular therapy programs.

My background includes a significant role with the NHSBT, Cord Blood Association and Precious Cells Group, where I developed biobanking and governance strategies in collaboration with NHS hospitals to advance stem cell collection, research, and application. I have also worked in the Regulatory field getting new cellular therapies approved by the United States FDA. My work also involves contributions to longevity science with Afrolongevity as a focus area. I am frequently engaged in international forums that address affordable and accessible cellular medicine and regenerative health care and aging issues. I am also involved with Connect Souq, the premier Professional networking marketplace for B2B e-commerce, with a reach spanning over 40 countries, contributing over \$3 trillion to the global economy by connecting 3 billion plus people globally.

### How would you describe the current state of the cell therapy landscape globally? Are there specific regions or countries that are leading the way?

The cell therapy landscape is rapidly evolving, with significant advancements in both research and clinical applications. While challenges remain, such as high production costs and complex manufacturing processes, the potential of cell therapies to revolutionize medicine is undeniable. Key trends include a growing number of clinical trials, increased investment in the sector, and the emergence of innovative technologies like CRISPR gene editing as well as creation of patient access and affordability organisations like Regenerative and cellular medicine registry (RCMR).

As regulatory frameworks evolve and reimbursement models adapt such as Global Regenerative Medicine Society (GRMS), cell therapies are poised to

become a cornerstone of modern medicine, offering transformative treatments for a wide range of diseases. Several regions and countries are at the forefront of cell and regenerative medicine research and development. The United States, with its robust biomedical research infrastructure and strong private sector investment, remains a global leader. Japan has made significant strides in this field, particularly in stem cell research and regenerative medicine, driven by government initiatives and a strong focus on innovation. South Korea has also emerged as a major player, with significant investments in biotechnology and a focus on clinical applications. Other key players include the United Kingdom, Germany, and China, each with its own unique strengths and contributions to the field, India to has an emerging research-based program and with its population diversity may be a major player.

### **What are the most promising types of cell therapies currently being developed?**

Some of the most promising types of cell therapies currently being developed include:

**CAR-T cell therapy:** This involves genetically engineering a patient's T cells to express a chimeric antigen receptor (CAR) that recognizes a specific antigen on cancer cells. CAR-T cell therapy has shown remarkable success in treating certain types of blood cancers.

**Stem cell therapy:** Stem cells have the potential to differentiate into various cell types, making them promise for regenerative medicine applications. They are being investigated for treating conditions like Parkinson's disease, spinal cord injuries, and heart disease, diabetes, sickle cell disease, liver regeneration and thalassemia.

**Induced pluripotent stem cell (iPSC) therapy:** iPSCs are generated from adult cells and can be differentiated into any cell type, offering a potential source of cells for transplantation and disease modelling.





**NK cell therapy:** Natural killer (NK) cells are a type of immune cell that can kill cancer cells. NK cell therapy involves engineering NK cells to enhance their ability to target and destroy cancer cells.

**Tissue engineering:** This involves combining cells, scaffolds, and growth factors to create functional tissues and organs. Tissue engineering has the potential to revolutionize the field of transplantation.

These are just a few examples of the many promising cell therapies currently under development. As research continues to advance, we can expect to see even more innovative and effective cell therapies emerge in the future.

**Are there specific conditions or diseases where cell therapy is showing the most potential (e.g., oncology, regenerative medicine)?**

Cell therapy is showing the most potential in two primary areas:


**Oncology:**

**Hematologic Malignancies:** CAR-T cell therapy has revolutionized the treatment of certain blood cancers like Leukemia and lymphoma, demonstrating remarkable efficacy in many patients.

**Solid Tumors:** While still in earlier stages of development, cell therapies targeting solid Tumors, such as those in the lung, pancreas, and brain, are showing promising results.

**Regenerative Medicine:**

- **Cardiovascular Diseases:** Stem cell therapy is being explored to repair damaged heart tissue and improve heart function after a heart attack.
- **Neurological Disorders:** Stem cell therapies are being investigated for treating conditions like Parkinson's disease, Alzheimer's disease, and spinal cord injuries.
- **Orthopaedic Conditions:** Cell therapies are being developed to regenerate cartilage and bone tissue, potentially leading to treatments for osteoarthritis and other joint disorders.
- It's important to note that while significant progress has been made, many challenges remain in translating these promising therapies into widespread clinical applications especially as accessibility and affordability remain a challenge. However, the future of cell therapy is bright, and we can expect to see continued advancements in the years to come including metabolic diseases.



### How do you see the development of cell therapies evolving in the next 5-10 years?

In my opinion in the next 5-10 years, we can expect significant advancements in cell therapies and regenerative medicine in particular areas such as:

#### 1. Personalized Medicine:

- Advanced Cell Therapies: Customized cell therapies tailored to individual patients' genetic makeup and disease characteristics will become more prevalent.
- Precision Medicine: By analysing a patient's genetic profile, doctors can select the most effective cell therapy and predict potential side effects.

#### 2. Tissue Engineering and Organ Regeneration:

- Bioengineered Organs: Progress in tissue engineering will enable the creation of complex organs like livers, kidneys, and hearts for transplantation.
- In-situ Tissue Repair: Stimulating the body's natural regenerative processes will be explored to repair damaged tissues without the need for transplants.

#### 3. Stem Cell Therapies:

- Expanded Applications: Stem cell therapies will expand beyond blood cancers and into solid Tumors, neurological disorders, and degenerative diseases.
- Improved Cell Sources: Novel sources of stem cells, such as induced pluripotent stem cells (iPSCs), will be further refined to enhance their therapeutic potential.

#### 4. Gene Editing Technologies:

- Precise Genome Editing: CRISPR-Cas9 and other gene editing tools will be used to correct genetic defects underlying diseases, leading to more effective cell therapies.
- Designer Cells: Genetically engineered cells with enhanced therapeutic properties will be developed.



- Overall, the future of cell therapies and regenerative medicine is promising. These advancements have the potential to revolutionize healthcare, offering new hope for patients with previously untreatable diseases.

**What are the primary challenges patients face in accessing cell therapy treatments? Are these challenges more related to regulatory barriers, cost, infrastructure, or awareness?**

The primary challenges which need to be addressed and will be addressed are:

**Regulatory Framework and Clinical Trials:**

- Accelerated Approval Processes: Regulatory agencies will continue to streamline the approval process for innovative cell therapies.
- Large-Scale Clinical Trials: Extensive clinical trials will be conducted to evaluate the safety and efficacy of cell therapies in diverse patient populations.

**Ethical Considerations and Public Perception:**

- Ethical Guidelines: Clear ethical guidelines will be established to ensure responsible use of cell therapies and regenerative medicine.
- Public Education and Awareness: Efforts will be made to educate the public about the benefits and risks of these technologies.

Patients face several significant challenges in accessing cell therapy treatments:

**High Production Costs:** The complex manufacturing processes involved in developing cell therapies, including cell isolation, culture, and genetic engineering, can be incredibly expensive.

**Limited Reimbursement:** Many health insurance plans may not fully cover the costs of cell therapies, leaving patients with substantial out-of-pocket expenses.

**Pricing Strategies:** Pharmaceutical companies often set high prices for these innovative treatments, further limiting patient access.

**Infrastructure:**

**Specialized Facilities:** Cell therapies require specialized manufacturing facilities and highly trained healthcare professionals to administer them. These facilities currently may not be readily available in all regions, particularly in developing countries.

**Logistical Challenges:** The complex planning involved in transporting cell therapies, especially those requiring specific temperature and handling conditions, can pose significant challenges.

**Limited Patient Awareness:** Many patients may not be aware of the potential benefits of cell therapies or the clinical trials available to them.

**Healthcare Provider Knowledge:** Some healthcare providers may not be fully informed about the latest advancements in cell therapy and may not recommend these treatments to their patients.

**Misconceptions:** There may be misconceptions about the safety and efficacy of cell therapies, which can deter patients from seeking these treatments.

Addressing these challenges requires a multi-faceted approach, including increased investment in research and development, improved reimbursement models which is being addressed by the Global Regenerative Medicine Society through its “Health Fund”, expanded access to specialized facilities with the likes of Umbilical Life Sciences in the UK and Kimera labs as well as Deverra will assist, and public education campaigns to raise awareness about the potential benefits of cell therapies will fall into the realm of the Regenerative and Cellular Medicine Registry, Cord Blood Association and other bodies.

### **How do you see the current regulatory environment impacting the accessibility of cell therapies? Are there specific regulations that are facilitating or hindering the adoption of cell therapies?**

The regulatory environment for cell therapies is constantly evolving. While some regulations are facilitating the development and adoption of these innovative treatments, others can pose challenges.

On one hand, regulatory agencies like the FDA have implemented streamlined approval processes for cell therapies such as RMAT, recognizing their potential to treat serious diseases. This has encouraged investment and accelerated clinical trials. However, the complex nature of cell therapies often requires extensive testing and documentation, which can be time-consuming and costly. Additionally, the high cost of manufacturing and administering cell therapies can hinder their accessibility, especially for patients in low-income countries.



Addressing these challenges requires a multi-faceted approach, including increased investment in research and development, improved reimbursement models which is being addressed by the Global Regenerative Medicine Society through its “Health Fund”, expanded access to specialized facilities with the likes of Umbilical Life Sciences in the UK and Kimera Labs Inc as well as Deverra Therapeutics in the United States will assist in the field. Public education campaigns to raise awareness about the potential benefits of cell therapies will fall into the realm of the Regenerative and Cellular Medicine Registry, DKMS, Cord Blood Association, and other bodies.

In conclusion, while the regulatory landscape is becoming more supportive of cell therapy development, there are still challenges to overcome to ensure widespread access to these life-saving treatments and governments are not interested currently in paying for these knowing the global economic challenges and geopolitical challenges.

#### **What role do you think public and private healthcare systems play in providing access to cell therapy?**

Public and private healthcare systems play a crucial role in providing access to cell therapy treatments. Public healthcare systems, like those in many United Kingdom and European countries, can help ensure that these treatments are accessible to a wider range of patients by subsidizing costs or providing free access. This can be particularly important for patients with serious conditions who may not be able to afford the prohibitive cost of cell therapy this can be done directly or through funding of a Global Health Fund such as the GRMS FUND.

Private healthcare systems, often found in countries like the United States, rely more on insurance coverage and individual finances. While this can lead to faster access to innovative treatments, it can also create significant financial burdens for patients. Organizations like the Global Regenerative Medicine Society can help bridge this gap by advocating for policies that promote equitable access to cell therapies and by fostering collaboration between public and private sectors through the creation of the “Global Health Fund.”

A combination of public and private initiatives is needed to ensure that cell therapies reach those who need them most. By working together, governments, healthcare providers, researchers, and patient advocacy groups can help make







these transformative treatments a reality for patients around the world.

### **Are there differences between regions or countries in terms of healthcare system support for cell therapy?**

Yes, there are significant differences between regions and countries in terms of healthcare system support for cell therapy.

#### **Developed Countries:**

The UK's National Health Service (NHS) has played a significant role in supporting the development and adoption of cell therapies. The NHS has invested in research and clinical trials, making the UK a leading centre for cell therapy research. However, access to cell therapies within the NHS can be influenced by several factors:

**NICE Guidelines:** The National Institute for Health and Care Excellence (NICE) assesses the cost-effectiveness of new treatments, including cell therapies. If a therapy is deemed cost-effective, it is more likely to be funded by the NHS.

**Clinical Trials:** Many cell therapies are still in the clinical trial phase. While the NHS often supports these trials, access to experimental therapies can be limited to eligible participants.

**Private Healthcare:** Patients may be able to access cell therapies through private healthcare providers, but this can be costly. The NHS has been supportive of cell therapy development and has made significant strides in improving patient access. However, challenges related to cost-effectiveness and limited availability may still hinder widespread adoption.



The United States: has a complex healthcare system with a mix of public and private insurance. While private insurance often covers cell therapies, the prohibitive cost can still be a barrier for many patients. Government initiatives like the 21st Century Cures Act have accelerated drug development, including cell therapies. European countries, particularly in Western Europe, have robust public healthcare systems that often cover the cost of cell therapies. However, access can vary depending on the specific country and the type of therapy.

In Asia Countries like Japan, South Korea, and Singapore have invested heavily in regenerative medicine and cell therapy research. They have established regulatory frameworks and supportive policies to encourage innovation and patient access. In South Asia, while cell therapy is a rapidly evolving field with significant potential, the level of support and accessibility varies significantly.

India has emerged as a global hub for medical tourism, attracting patients from around the world seeking affordable and high-quality healthcare. The private sector plays a key role in healthcare delivery, including cell therapy treatments. The government has recognized the potential of regenerative medicine and has taken steps to promote research and development in this field.

As for other countries in the region including Pakistan, Bangladesh, and Sri Lanka These countries have developing healthcare systems with limited resources and infrastructure.

There is growing interest in cell therapy in these countries, but the availability of advanced treatments and their accessibility to the general population remains a challenge.

Governments in these countries are taking steps to improve healthcare infrastructure and access to advanced treatments, including cell therapy. However, significant challenges remain, such as a lack of skilled professionals, inadequate regulatory frameworks, and limited funding.

While India has made significant strides in the field of cell therapy, other South Asian countries are still in the preliminary stages of development. Improve access to these treatments, these countries need to focus on strengthening their healthcare infrastructure, investing in research and development, and implementing supportive policies.

The Gulf Cooperation Council (GCC) countries, including Saudi Arabia and the UAE, have been actively investing in healthcare infrastructure and innovative medical technologies, including cell therapy. These countries have recognized the potential



of cell therapy to treat a wide range of diseases and have taken steps to support its development and accessibility.

Governments in the GCC have allocated significant funds for healthcare initiatives, including research and development in regenerative medicine. This has led to the establishment of specialized research centers and hospitals equipped to conduct clinical trials and provide cell therapy treatments.

Private investors and healthcare providers have also shown keen interest in cell therapy. This has resulted in the development of private clinics and hospitals offering advanced cell therapy treatments.

While the regulatory landscape for cell therapies is still evolving in the region, efforts are being made to establish clear guidelines and regulations to ensure the safety and efficacy of these treatments.

Many GCC countries have comprehensive healthcare insurance systems that cover a wide range of medical treatments, including cell therapy. However, the specific coverage and reimbursement policies can vary.

In general, the GCC countries have a positive outlook for the development and accessibility of cell therapy. With continued government support, private sector investment, and regulatory advancements as well as collaborating with the regenerative and cellular medicine registry, the region is well-positioned to become a global leader in cell therapy research and clinical applications.

### **Developing Countries:**

Developing countries face unique challenges in accessing cell therapies. Limited healthcare infrastructure, economic constraints, and a lack of awareness can hinder the adoption of these treatments. However, some countries are making efforts to develop their own cell therapy capabilities and collaborate with international partners to improve patient access.

The Global Regenerative Medicine Society plays a crucial role in addressing these disparities by promoting collaboration, advocating for equitable access, and supporting research and development in low- and middle-income countries such as Tanzania, South Africa, Kenya, Zambia, Mozambique, Botswana, Morocco

and Egypt in Africa and Mexico, Brazil in South America.

**What are the key economic factors (e.g., cost of production, pricing, reimbursement) that impact patient access to cell therapies?**

The prohibitive cost of production is a major economic factor impacting patient access to cell therapies. The complex manufacturing processes, including cell isolation, culture, and genetic engineering, require significant investment in specialized facilities and skilled personnel. Additionally, the need for rigorous quality control and regulatory compliance further increases production costs. Pricing is another crucial factor. BioPharma companies often set soaring prices for cell therapies, reflecting the substantial research and development costs involved. However, these high prices can limit patient access, especially in countries with less robust healthcare systems or where insurance coverage is limited.

Reimbursement policies play a critical role in determining patient access. Healthcare payers, such as insurance companies and government programs, often face challenges in evaluating the long-term value and cost-effectiveness of cell therapies. Traditional reimbursement models may not be suitable for these one-time, potentially curative treatments. Innovative payment models, such as outcome-based payments or risk-sharing agreements, are being explored to address these challenges and improve patient access.

**From your experience, how well are healthcare providers equipped to deliver cell therapy treatments?**

While healthcare providers are increasingly becoming more equipped to deliver cell therapy treatments, there are still significant challenges. Many providers lack the specialized knowledge and training required to administer these complex therapies. Additionally, the infrastructure needed to store, transport, and administer cell therapies can be costly and difficult to establish. As the field of cell therapy continues to advance, it is crucial to invest in training programs for healthcare professionals and to develop standardized protocols for the delivery of these treatments.

**Are there gaps in training, infrastructure, or availability of specialized centers?**

Yes, there are significant gaps in training, infrastructure, and the availability of





specialized cell therapy centers. Many healthcare providers, particularly in regions with less developed healthcare systems, lack the specialized knowledge and skills required to administer complex cell therapies. Additionally, the infrastructure needed to produce, store, and transport these therapies, including specialized laboratories and cold chain planning, may not be readily available. The limited availability of specialized cell therapy centers further restricts patient access, particularly in rural and underserved areas.

### **How aware are patients and providers of the potential benefits and risks associated with cell therapies?**

While awareness of cell therapies has increased in recent years, there are still gaps in patient and provider understanding of the potential benefits and risks associated with these treatments. Many patients may not be fully informed about the specific indications, efficacy, and potential side effects of different cell therapies. Misconceptions and unrealistic expectations can lead to disappointment and frustration.

Healthcare providers, including physicians and nurses, also need to be well-informed about the latest advancements in cell therapy. This requires ongoing education and training to ensure that they can accurately assess patient eligibility, provide appropriate counselling, and manage potential complications. By improving patient and provider education, we can help to optimize the use of cell therapies and maximize their benefits.

### **What can be done to improve awareness and education?**

Improving awareness and education about cell therapy and regenerative medicine is essential for promoting patient understanding, encouraging informed decision-making, and facilitating the adoption of these innovative treatments.

Firstly, public awareness campaigns can play a significant role in disseminating information about the potential benefits and risks of cell therapy. These campaigns should be conducted through various channels, including television, radio, print media, and social media. Engaging and informative content, such as patient testimonials and expert interviews, can help to dispel myths and misconceptions.

Secondly, healthcare providers should be encouraged to participate in con-

tinuing education programs to stay up to date on the latest advancements in cell therapy and regenerative medicine. These programs can be organized by medical societies, pharmaceutical companies, and academic institutions. By acquiring the necessary knowledge and skills, healthcare providers can effectively communicate with patients about treatment options and manage potential complications.

Thirdly, patient advocacy organizations can play a vital role in educating patients and their families about cell therapy. These organizations can provide information about clinical trials, support groups, and financial assistance programs. They can also advocate for policies that promote access to cell therapy and ensure patient safety.

Finally, collaboration between researchers, clinicians, industry representatives, and policymakers is essential to advance the field of cell therapy and improve patient access. By sharing knowledge and resources, these stakeholders can accelerate the development of new therapies, streamline regulatory processes, and reduce costs. The RCMR and GRMS are well poised to do this through the Connect Souq platform connecting eight billion people globally through ethical education.

### **Do you see disparities in access to cell therapy based on geographic location, socioeconomic status, or other factors?**

Yes, there are significant disparities in access to cell therapy based on geographic location, socioeconomic, ethnicity, status, and other factors. Geographic disparities arise due to the uneven distribution of specialized healthcare facilities equipped to administer cell therapies. Patients in rural or underserved areas may have limited access to these treatments, requiring them to travel long distances to specialized centers.

Socioeconomic disparities also play a crucial role. The prohibitive cost of cell therapies can be a significant barrier for patients with lower incomes or inadequate insurance coverage.



Additionally, disparities in healthcare literacy and access to information can hinder patient understanding of treatment options and hinder their ability to make informed decisions.

Other factors, such as age, race, and ethnicity, are also major influencers to access to cell therapy. For example, older patients may face challenges related to comorbidities and reduced physical fitness, while ethnic populations are under-represented on registries and therefore in clinical trials and have limited access to specialized care. The Regenerative and Cellular Medicine Registry is the only comprehensive regenerative therapies cell registry addressing this ([www.rcmregistry.com](http://www.rcmregistry.com))

### **What strategies can be implemented to address these disparities?**

Address disparities in access to cell therapy, several strategies can be implemented:

Firstly, expanding access to specialized healthcare facilities and healthcare providers is crucial. This can be achieved through investments in infrastructure, training programs for healthcare professionals, and telemedicine initiatives to connect patients in remote areas with specialists. Additionally, efforts should be made to reduce the cost of cell therapies through innovative payment models, such as GRMS Health Find, outcome-based payments or risk-sharing agreements.

Secondly, patient education and outreach programs can help to bridge the knowledge gap and empower patients to make informed decisions about their treatment options. These programs should be tailored to the specific needs of different populations, considering factors like language, cultural background, and literacy level which RCMR is developing. By addressing these disparities, we can ensure that cell therapy benefits are more equitably distributed and that all patients can access these life-changing treatments.


### **What innovations (technological or procedural) do you believe will have the greatest impact on improving access to cell therapies?**

Several technological and procedural innovations have the potential to significantly improve access to cell therapies:

Technological Innovations:

**Automation and Robotics:** Automation of cell manufacturing processes can reduce costs, increase efficiency, and improve consistency.

**Advanced Bioreactors:** Improved bioreactor designs can enhance cell growth and



production, leading to higher yields and lower costs.

**Point-of-Care Cell Therapies:** Developing portable devices for cell therapy administration can expand access to patients in remote areas.

**Artificial Intelligence and Machine Learning:** AI can optimize cell therapy production, predict treatment outcomes, and personalize treatment plans with better algorithms.

**Procedural Innovations:**

**Streamlined Regulatory Processes:** Simplified regulatory pathways can accelerate the development and approval of cell therapies.

**Innovative Reimbursement Models:** Flexible reimbursement models, such as outcome-based payments, can incentivize the adoption of cell therapies.

**Public-Private Partnerships:** Collaborations between academia, industry, and government can drive innovation and facilitate the translation of research into clinical applications.

**Global Collaboration:** International cooperation can share knowledge, resources, and best practices to improve access to cell therapies worldwide.

By leveraging these technological and procedural advancements, we can work towards a future where cell therapies are accessible to more patients, regardless of their geographic location or socioeconomic status.

### **Are there any novel delivery models (e.g., decentralized manufacturing, telemedicine) that could enhance access?**

Yes, several novel delivery models have the potential to enhance access to cell therapies:

**Decentralized Manufacturing:**

**Regional Manufacturing Hubs:** Establishing regional manufacturing hubs can reduce transportation costs and improve access for patients in remote areas.







**Point-of-Care Manufacturing:** Developing technologies for on-site cell processing and administration can streamline the delivery process and reduce delays.

**Telemedicine:**

**Remote Monitoring:** Telemedicine can be used to monitor patients remotely, reducing the need for frequent hospital visits and improving access to specialized care.

**Virtual Consultations:** Telemedicine consultations can facilitate communication between patients and healthcare providers, especially in rural areas.

**Hybrid Models:**

**Hub-and-Spoke Model:** Combining centralized manufacturing with decentralized administration can optimize resource utilization and improve patient access.

**Collaborative Networks:** Partnerships between academic institutions, healthcare providers, and industry can foster innovation and facilitate the development of new delivery models.

By implementing these novel delivery models, we can overcome the challenges associated with traditional cell therapy delivery and make these life-saving treatments more accessible to patients worldwide.

### **What roles do partnerships between academia, industry, and government play in facilitating broader access to cell therapies?**

Partnerships between academia, industry, and government play a pivotal role in facilitating broader access to cell therapies. By combining their unique strengths and resources, these entities can accelerate research, streamline regulatory processes, and reduce costs.

Academic institutions are at the forefront of basic research, generating groundbreaking discoveries and developing innovative cell therapy technologies as we witnessed during the COVID pandemic. Industry partners, with their expertise in manufacturing, clinical development, and commercialization, can translate these discoveries into marketable products. Government agencies can provide funding, regulatory support, and infrastructure to foster innovation and ensure patient safety.

Through collaborative efforts, these partners can address the challenges associated with cell therapy development and commercialization. For instance, they can work together to establish standardized manufacturing processes, develop robust quality control systems, and streamline regulatory pathways. By sharing knowledge and resources, they can accelerate the development of new cell therapies and reduce time-to-market.

### **How important is it to include patient advocacy groups in the conversation around access to cell therapies? What role can these groups play in shaping policy and improving patient outcomes?**

Patient advocacy groups play a crucial role in the conversation around access to cell therapies. These groups represent the voices of patients and their families, ensuring that their needs and concerns are heard and addressed. By working together with healthcare providers, researchers, and policymakers, patient advocacy groups can help shape policies that improve patient access to cell therapies.

One of the key roles of patient advocacy groups is to raise awareness about cell therapies and their potential benefits. They can educate the public about the latest advancements in the field, dispel myths and misconceptions, and empower patients to make informed decisions about their treatment options. By increasing public awareness, these groups can help to generate support for research and development, as well as for policies that promote equitable access to cell therapies.

Another key role of patient advocacy groups is to advocate for policies that support patient access to cell therapies. This includes advocating for fair pricing, streamlined regulatory processes, and increased insurance coverage. By collaborating with policymakers, these groups can help to shape a regulatory environment that encourages innovation and facilitates the adoption of new cell therapies.

Lastly, patient advocacy groups can provide essential support to patients and their families. They can offer information and resources, connect patients with clinical trials, and provide emotional support. By working closely with healthcare providers, these groups can help to improve the quality of care and enhance the patient experience.



## In your opinion, what are the top three actions that can be taken to improve access to cell therapies globally?

### 1.Reduce Production Costs and Increase Accessibility:

**Advancements in Technology:** Investing in research and development to improve manufacturing processes, such as automation and bioreactor optimization, can significantly reduce production costs.

**Global Collaboration:** Fostering international collaborations between researchers, clinicians, and industry partners can facilitate knowledge sharing, resource optimization, and the establishment of global supply chains through a single registry.

**Innovative Payment Models:** Exploring alternative payment models, like the Global Health Fund, outcome-based pricing or value-based healthcare, can incentivize the development of cost-effective therapies and improve patient access.

### 2.Expand Healthcare Infrastructure and Workforce:

**Investment in Training and Education:** Supporting training programs for healthcare professionals, including physicians, nurses, and technicians, can ensure a skilled workforce capable of delivering cell therapies.

**Development of Specialized Facilities:** Investing in the development of specialized facilities, such as cell therapy manufacturing centers and clinical trial sites, can expand access to these treatments, particularly in underserved regions.

**Telemedicine and Remote Monitoring:** Leveraging telemedicine can improve access to specialized care, especially for patients in rural or remote areas.

### 3.Enhance Patient Awareness and Education:

**Public Awareness Campaigns:** Implementing public awareness campaigns can educate the public about the potential benefits and risks of cell therapies, dispel misconceptions, and encourage early diagnosis and treatment.

**Patient Advocacy Groups:** Supporting patient advocacy groups can empower patients to advocate for their own needs and improve access to care.

**Healthcare Provider Education:** Providing continuing education programs for healthcare providers can ensure that they have the latest information on cell therapy advancements and can effectively communicate with patients about treatment options.





### **Looking ahead, what do you think will be the most critical issue in expanding access to cell therapy treatments?**

One of the most critical issues in expanding access to cell therapy treatments is the prohibitive cost of production and administration. The complex manufacturing processes, specialized facilities, and skilled personnel required to produce cell therapies contribute to their prohibitive cost. Additionally, the individualized nature of many cell therapies necessitates extensive testing and quality control, further increasing expenses.

Address this challenge, innovative approaches such as automated manufacturing, standardized protocols, and economies of scale can help reduce production costs. Furthermore, exploring alternative payment models, as discussed in earlier questions, can make cell therapies more affordable for patients and healthcare systems.

### **How should the industry and regulators prepare for future challenges?**

To prepare for future challenges, the industry and regulators must adopt an initiative-taking and collaborative approach. Firstly, continued investment in research and development is essential to drive innovation and develop more effective and affordable cell therapies. This includes supporting basic research, clinical trials, and the development of advanced manufacturing technologies.

Secondly, global harmonization of regulations and standards is crucial to facilitate the seamless development and commercialization of cell therapies across different regions. By aligning regulatory requirements and quality standards, we can reduce regulatory burdens and expedite the approval process. International collaborations between regulatory agencies can help to establish common guidelines and facilitate the exchange of best practices.

Finally, patient engagement and education are vital to ensure the successful adoption of cell therapies. By involving patients and their families in the development and delivery of these treatments, we can address their concerns and improve their understanding of the benefits and risks. Additionally, patient advocacy groups can play a crucial role in advocating for policies that support access to cell therapies and improve patient outcomes.

**What role do you see for emerging markets in the global cell therapy landscape? Are there lessons that can be learned from countries that have been successful in improving access to advanced therapies?**

Emerging markets have a significant role to play in the global cell therapy landscape. They offer a vast patient population with unmet medical needs, a growing middle class with increasing disposable income, and a favourable regulatory environment for innovation.

Countries like Singapore and South Korea have successfully positioned themselves as global hubs for cell therapy research and development. Key lessons that can be learned from these countries include:

**Strong Government Support:** Government initiatives, such as funding research, establishing regulatory frameworks, and providing tax incentives, can significantly accelerate the development and commercialization of cell therapies.

**Collaboration between Academia, Industry, and Government:** Fostering strong partnerships between these key stakeholders can facilitate knowledge sharing, resource optimization, and the rapid translation of research into clinical applications.

**Investment in Infrastructure and Talent:** Developing world-class research facilities, training programs for healthcare professionals, and a robust regulatory framework are essential for attracting investment and fostering innovation.

**Patient-Centric Approach:** Prioritizing patient needs and engaging with patient advocacy groups can help to ensure that cell therapies are developed and delivered in a way that maximizes patient benefit.

By learning from the successes of these countries, emerging markets can accelerate their progress in cell therapy and provide hope to millions of patients.



**Do you have any final thoughts on the future of cell therapy, particularly in terms of patient access and equity?**

The future of cell therapy holds immense promise, but it is imperative to ensure equitable access for all patients, regardless of their geographic location or socioeconomic status. While significant advancements are being made, challenges such as high costs, complex manufacturing processes, and limited healthcare infrastructure persist.

To address these challenges, it is crucial to prioritize global collaboration, invest in research and development, and implement innovative delivery models. By working together, researchers, clinicians, industry leaders, policymakers, and patient advocacy groups can accelerate the development and deployment of cell therapies.

The goal is to create a future where cell therapies are accessible to all who need them, transforming the lives of countless patients and revolutionizing the field of medicine.





## ABOUT TECHSCI HEALTHCARE

TechSci Healthcare vertical offers market research & consulting services in the healthcare industry with a major focus on pharmaceuticals, medical devices, consumer healthcare, animal healthcare, biotechnology, and healthcare IT domains. TechSci Research also focuses on providing market intelligence on emerging technologies and niche industries that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.

## AUTHORS



Karan Chechi

Research Director



Shaurya Singh

Senior Research Analyst



Manvi Suri

Junior Research Analyst